



Contact

Fangli Chen, Ph.D.

Partner

Boston

+1.617.526.9633

fchen@proskauer.com

Dr. Fangli Chen is a partner in the Litigation Department and vice chair of the Life Sciences Patent Practice. Dr. Chen represents all types of companies in the biotech and pharmaceutical industries, and has deep scientific expertise and a strong business sense. She effectively identifies and transforms technological developments into valuable intellectual property assets for her clients and specializes in the strategic development of complex IP portfolios for companies that align with their business goals.

The primary focus of her practice is intellectual property prosecution, which includes strategic development of complex patent portfolios for companies, universities and research institutions. She prepares and prosecutes patent applications in the fields of biochemistry, molecular and cell biology, immunology, biochemical and molecular diagnostics, pharmaceuticals, microbiology, molecular genetics, pharmacogenomics, recombinant technologies, enzyme replacement therapy, messenger RNA therapy, gene therapy, bioinformatics, drug discovery, medical devices and chemistry; performs due diligence investigations, and provides freedom-to-operate studies, non-infringement and invalidity analysis.

Dr. Chen also has a wealth of experience in the following areas:

- Post-grant challenges: representing clients in *inter partes* review interference

and various foreign opposition proceedings.

- Technology transactions & licensing: advising clients on matters relating to technology or material transfer, licensing and research collaborations.
- Investment or acquisition counsel: assisting investors in assessing the technology and intellectual property assets and risks for potential target investments and counseling companies on intellectual property matters in connection with public offering or acquisition.

Prior to joining Proskauer, Dr. Chen was a partner at a leading Boston law firm. Dr. Chen has been recognized for client service excellence in 2015 by *Client Choice*, and has been named an “Up & Coming Lawyer” by *Massachusetts Lawyers Weekly*, a *Massachusetts Super Lawyers Rising Star* and a World’s Leading Patent Practitioner by *IAM Patent 1000*. She has also been listed in *Best Lawyers in America*, and recognized by *Managing Intellectual Property* as one of the “Top 250 Women in IP” nationwide.

[Close](#)

Matters

Representative Matters

- Representation of a biotech company in defending its key patent in *inter partes* review.
- Strategic representation of large biopharmaceutical company with regard to their product protection, life cycle management, clearance study and IP diligence in connection with acquisition, license and other business partnership.
- Strategic representation of biotech start-up company with regard to protection of their key product, freedom-to-operate and management of their relationship with large biotech partners.
- IP counsel to pharmaceutical companies and universities for managing portfolios in areas of pharmacogenomics, recombinant technologies, molecular biology, bioinformatics, drug discovery and small molecules.

Practices

Intellectual Property, Patent Law

Industries

Life Sciences, Health Care

Education

Suffolk University Law School, J.D., 2006

cum laude

Massachusetts Institute of Technology, Ph.D., 2001

Oklahoma State University, M.S., 1995

Fudan University, B.S., 1990

highest distinction

Admissions & Qualifications

Massachusetts

U.S. Patent and Trademark Office

Court Admissions

U.S. District Court, Massachusetts

U.S. Court of Appeals, Federal Circuit

Awards & Recognition

Best Lawyers in America 2016-2020

IAM Patent 1000: The World's Leading Patent Practitioners 2016-2018

Client Choice 2015

Massachusetts Lawyers Weekly, "Top Women of Law" 2017-2018

Massachusetts Lawyers Weekly, "Up & Coming Lawyer"

Massachusetts Super Lawyers, "Super Lawyer" 2017-2018

Managing Intellectual Property, "Top 250 Women in IP" nationwide

LMG Life Sciences: Life Sciences Star 2017-2018

The Legal 500 United States: Healthcare: Life Sciences 2019